Details for Patent: 8,754,109
✉ Email this page to a colleague
Which drugs does patent 8,754,109 protect, and when does it expire?
Patent 8,754,109 protects ESBRIET and is included in two NDAs.
This patent has forty patent family members in thirty countries.
Summary for Patent: 8,754,109
Title: | Pirfenidone therapy and inducers of cytochrome P450 |
Abstract: | The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking. |
Inventor(s): | Bradford; Williamson Z. (Ross, CA), Szwarcberg; Javier (San Francisco, CA) |
Assignee: | Intermune, Inc. (Brisbane, CA) |
Application Number: | 13/513,472 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,754,109 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,754,109
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genentech Inc | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER | ⤷ Sign Up | |||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY | ⤷ Sign Up | |||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,754,109
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
10250378 | Mar 3, 2010 | |
Canada | 2710014 | Oct 8, 2010 |
PCT Information | |||
PCT Filed | December 03, 2010 | PCT Application Number: | PCT/US2010/058936 |
PCT Publication Date: | June 09, 2011 | PCT Publication Number: | WO2011/069089 |
International Family Members for US Patent 8,754,109
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | E523197 | ⤷ Sign Up | |||
Australia | 2010212488 | ⤷ Sign Up | |||
Brazil | 112012013155 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |